Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea.

Jae-Seok MinChang Min LeeSung Il ChoiKyung Won SeoDo Joong ParkYong Hae BaikMyoung-Won SonWon Hyuk ChoiSungsoo KimKyung Ho PakMin Gyu KimJoong-Min ParkSang Ho JeongMoon-Soo LeeSungsoo Park

Published in: Journal of gastric cancer (2018)

S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.

Keyphrases

primary care
current status
healthcare
emergency department
combination therapy
randomized controlled trial
young adults
replacement therapy
palliative care
study protocol
childhood cancer